Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1594

Volumetric Bioprinting

Recreating human body parts using a 3D printer. This is possible in the Netherlands with the new bioprinter developed by Utrecht University and UMC Utrecht. This printer can be used to make models of organs or bones, amongst other things. These printed models can be made up of living cells on which medication can be tested, for instance.

Conventional 3D printers work by stacking plastic layers on top of each other. This build-up of layers creates a three-dimensional figure. There are already countless possibilities with these standard 3D printers. Science has been looking for years at how this technique can be applied across different areas.

Printing living cells

Continue reading “Ultra-fast 3D bioprinter makes body parts in a flash” | >

September 14, 2020 — The use of artificial intelligence (AI) in radiology to aid in image interpretation tasks is evolving, but many of the old factors and concepts from the computer-aided detection (CAD) era still remain, according to a Sunday talk at the Conference on Machine Intelligence in Medical Imaging (C-MIMI).

A lot has changed as the new era of AI has emerged, such as faster computers, larger image datasets, and more advanced algorithms — including deep learning. Another thing that’s changed is the realization of additional reasons and means to incorporate AI into clinical practice, according to Maryellen Giger, PhD, of the University of Chicago. What’s more, AI is also being developed for a broader range of clinical questions, more imaging modalities, and more diseases, she said.

At the same time, many of the issues are the same as those faced in the era of CAD. There are the same clinical tasks of detection, diagnosis, and response assessment, as well as the same concern of “garbage in, garbage out,” she said. What’s more, there’s the same potential for off-label use of the software, and the same methods for statistical evaluations.

Read more | >

“It is completely preserved, with all internal organs in place, including even its nose,” and a preliminary analysis reveals it lived 22,000 to 39,500 years ago… See More.

In a statement issued by the university, researcher Lena Grigorieva emphasized that “this is the first and only find of its kind — a whole bear carcass with soft tissues.”

“It is completely preserved, with all internal organs in place, including even its nose,” Grigorieva said. “This find is of great importance for the whole world.”

A preliminary analysis indicated that the adult bear lived 22,000 to 39,500 years ago.

Continue reading “‘Completely preserved’ Ice Age cave bear found in Arctic Russia” | >

O,.o.

“It’s going to take four to five years until everyone gets the vaccine on this planet,” Adar Poonawalla, chief executive of the Serum Institute of India, told the newspaper.

Dragging down the feasibility, Poonwalla says that such a vaccine would likely need to include a second booster shot, like for the measles or rotavirus vaccine. That would mean 15 billion doses in total for the entire globe.

“I know the world wants to be optimistic on it… [but] I have not heard of anyone coming even close to that [level] right now,” Poonawalla added.

Continue reading “There Won’t Be Enough COVID Vaccines for Everybody Until 2024, Warn Vaccine Makers” | >

Anti-bacterial efficiency close to 100% under 10-min sunlight and promising results in deactivation of coronaviruses.

Face masks have become an important tool in fighting against the COVID-19 pandemic. However, improper use or disposal of masks may lead to “secondary transmission.” A research team from City University of Hong Kong (CityU) has successfully produced graphene masks with an anti-bacterial efficiency of 80%, which can be enhanced to almost 100% with exposure to sunlight for around 10 minutes. Initial tests also showed very promising results in the deactivation of two species of coronaviruses. The graphene masks are easily produced at low cost, and can help to resolve the problems of sourcing raw materials and disposing of non-biodegradable masks.

The research is conducted by Dr. Ye Ruquan, Assistant Professor from CityU’s Department of Chemistry, in collaboration with other researchers. The findings were published in the scientific journal ACS Nano, titled “Self-Reporting and Photothermally Enhanced Rapid Bacterial Killing on a Laser-Induced Graphene Mask.”

Read more | >

When Sartre said hell is other people, he wasn’t living through 2020. Right now, other people are the only thing between us and species collapse. Not just the people we occasionally encounter behind fugly masks—but the experts and innovators out in the world, leading the way. The 17-year-old hacker building his own coronavirus tracker. The Google AI wonk un-coding machine bias. A former IT guy helping his community thwart surveillance. There are people everywhere, in and out … See More.

The scientists, technologists, artists, and chefs who are standing between us and species collapse.

Read more | >

TLDR: Scroll down to Conclusions.

Elon Musk has recently unveiled his company’s first Neuralink device implanted in an experimental animal — a pig.

To briefly describe the device for those without much technical knowledge, it is an invasive technology based on the concept of a neural lace, which is a mesh of perhaps hundreds of wires laced throughout the brain albeit with concentration of connections in certain areas. These either sample neural patterns or modify them. Needless to say, even the minor technical challenges are massive. For example, it involves brain surgery. Then we have bio-compatibility problems as typically implanted electrodes tend to cause the tissues around them to die back. Finally, actually transferring massive amounts of data through the skull to and from an implanted and (presumably) powered computer. Elon Musk may well be able to solve these problems since they are not new technical challenges and a considerable amount of work has already been done in this area. Even automating the brain surgery may well be feasible using robotics.

Read more | >

Summary: Glial cells not only control the speed of nerve conduction, but they also influence the precision of signal transduction.

Source: University of Münster

For the brain to work efficiently, it is important that a nerve impulse arrives at its destination as quickly and as precisely as possible. It has been long been known that the nerve fibres — also known as axons — pass on these impulses. In the course of evolution, an insulating sheath — myelin — developed around the axons which increases the speed of conduction. This insulating sheath is formed by the second type of cell in the nervous system — the glial cells, which are one of the main components of the brain. If, as a result of disease, myelin is depleted, this leads to neurological disorders such as Multiple Sclerosis or Morbus Charcot-Marie-Tooth.

Read more | >

Canada reported no new deaths from COVID-19 on Friday for the first time in six months. The last time the country reported no new deaths from the virus on March 15, at the start of lockdowns in North America due to the pandemic, Reuters reports.

As of Friday evening, over 6 million people had been tested for COVID-19 in Canada, 2.1% of which came back positive. Some 702 new cases were reported on Friday, but no new deaths, the Public Health Agency of Canada reported.

Read more | >

An early analysis of the data, which did not include patients enrolled later in the trial, found that median time to recovery was 11 days for patients on remdesivir and 15 days for patients on placebo. It also suggested a lower death rate, 8 percent on remdesivir compared to 11.6 percent on placebo, but that difference was just short of statistical significance.

UCSF and Zuckerberg San Francisco General Hospital together enrolled about 30 patients in the NIH trial. Because the trial was double-blinded, neither the doctors nor the patients knew which patients received remdesivir or placebo. With survival rates in San Francisco relatively high compared to harder hit cities, it was hard to attribute any specific improvement to the drug, said Chin-Hong and Doernberg, who both cared for patients in the trial.

“We’re talking about a couple days of faster recovery overall, so in any one particular patient, that may not be so apparent,” said Doernberg. “This is why you have to do large trials.”

Read more | >